Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Net Cash Flow (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Net Cash Flow for 6 consecutive years, with -$7.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 47.01% year-over-year to -$7.8 million, compared with a TTM value of $5.6 million through Sep 2025, up 113.15%, and an annual FY2024 reading of -$784000.0, up 95.6% over the prior year.
  • Net Cash Flow was -$7.8 million for Q3 2025 at Ovid Therapeutics, down from $7.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $161.0 million in Q1 2021 and bottomed at -$93.9 million in Q2 2022.
  • Average Net Cash Flow over 5 years is -$2.6 million, with a median of -$10.4 million recorded in 2021.
  • The sharpest move saw Net Cash Flow soared 1205.87% in 2021, then plummeted 349.4% in 2022.
  • Year by year, Net Cash Flow stood at -$12.1 million in 2021, then dropped by 11.1% to -$13.4 million in 2022, then crashed by 127.01% to -$30.4 million in 2023, then surged by 136.98% to $11.2 million in 2024, then tumbled by 169.2% to -$7.8 million in 2025.
  • Business Quant data shows Net Cash Flow for OVID at -$7.8 million in Q3 2025, $7.3 million in Q2 2025, and -$5.2 million in Q1 2025.